Astellas Pharma Inc. Stock

Equities

4503

JP3942400007

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-06-17 am EDT 5-day change 1st Jan Change
1,510 JPY +0.50% Intraday chart for Astellas Pharma Inc. -5.06% -10.47%
Sales 2024 1,604B 10.18B Sales 2025 * 1,674B 10.63B Capitalization 2,693B 17.1B
Net income 2024 17.04B 108M Net income 2025 * 73.23B 465M EV / Sales 2024 1.63 x
Net Debt 2024 336B 2.13B Net Debt 2025 * 479B 3.04B EV / Sales 2025 * 1.89 x
P/E ratio 2024
173 x
P/E ratio 2025 *
36.8 x
Employees 14,484
Yield 2024
4.26%
Yield 2025 *
4.98%
Free-Float 98.84%
More Fundamentals * Assessed data
Dynamic Chart
US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab MT
U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.? Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date CI
Astellas Announces Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies CI
Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea DJ
Astellas Unveils New, State-Of-The-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor CI
Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos MT
Malin Corp investee signs agreement with Astellas Pharma AN
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences DJ
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion RE
Transcript : Astellas Pharma Inc., 2024 Earnings Call, Apr 25, 2024
Astellas Pharma Inc. Declares Year End Dividend for the Year Ended March 31, 2023 and Provides Interim and Year End Dividend Guidance for the Fiscal Year 2024 CI
Astellas Pharma Inc. Provides Consolidated Earnings Guidance on Full Basis for the Full-Year 2024 CI
Astellas Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Astellas Pharma Inc. Announces Board and Committee Retirements CI
European Commission Approves Astellas Pharma Label Extension for Xtandi MT
More news
1 day+0.50%
1 week-4.25%
Current month-2.52%
1 month+1.51%
3 months-7.73%
6 months-7.53%
Current year-10.47%
More quotes
1 week
1 482.00
Extreme 1482
1 596.50
1 month
1 482.00
Extreme 1482
1 602.50
Current year
1 426.00
Extreme 1426
1 801.50
1 year
1 426.00
Extreme 1426
2 305.00
3 years
1 426.00
Extreme 1426
2 360.50
5 years
1 375.00
Extreme 1375
2 360.50
10 years
1 288.00
Extreme 1288
2 360.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 86-03-31
Director of Finance/CFO 52 Oct. 31
Chairman 64 86-03-31
Members of the board TitleAgeSince
Chairman 64 86-03-31
Chief Executive Officer 61 86-03-31
Director/Board Member 68 19-05-31
More insiders
Date Price Change Volume
24-06-17 1,510 +0.50% 4 709 900
24-06-14 1,502 -0.30% 11,925,300
24-06-13 1,506 -3.86% 8,194,700
24-06-12 1,567 -0.76% 4,191,000
24-06-11 1,579 +0.16% 5,214,100

Delayed Quote Japan Exchange, June 17, 2024 at 02:00 am EDT

More quotes
Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders. Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
1,502 JPY
Average target price
1,938 JPY
Spread / Average Target
+28.99%
Consensus